Biochem/physiol Actions
Histone deacetylases inhibitor against class I (HDAC1/2/3/8), IIB (HDAC6/10), IV (HDAC11) HDACs with anti-cancer and HIV latency reativation potency.
MC1742 is a uracil-based hydroxyamide (UBHA) that acts as a subtype-selective histone deacetylases (HDACs) inhibitor (IC50: class I HDAC1/2/3/8 = 100/110/20/610 nM, class IIB HDAC6/10 = 7/40 nM, class IV HDAC11 = 100 nM, class IIA HDAC4/5/7/9 >50 μM). MC1742 exerts greater antiproliferation potency than SAHA in sarcoma cancer stem cell (CSC) cultures (MC1742/SAHA IC50 in μM = 0.25/1/RD, 1.12/1.13//MG-63, 1.4/3.92/SK-ES-1 post 72-hr treatment) and effectively reactivates HIV from latency (EC50 = 350 nM; JLAT 10.6 cells) by upregulating histone acetylation at the HIV promoter without activating T cells.
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | 2-8°C |
| SMILES string | S(CCCCC(=O)NO)c1[nH][c](cc(n1)c2ccc(cc2)c3ccccc3)=O |
| InChI | 1S/C21H21N3O3S/c25-19(24-27)8-4-5-13-28-21-22-18(14-20(26)23-21)17-11-9-16(10-12-17)15-6-2-1-3-7-15/h1-3,6-7,9-12,14,27H,4-5,8,13H2,(H,24,25)(H,22,23,26) |
| InChI key | AOFVDNFTELWRHV-UHFFFAOYSA-N |
